Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Repligen Corporation (RGEN)
Repligen Corporation stock price live, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Repligen Corporation real time stock price chart below.
What Is the Repligen Corporation Stock Price Today?
The Repligen Corporation stock price today is 174.86.
What Is the Stock Symbol for Repligen Corporation?
The stock ticker symbol for Repligen Corporation is RGEN.
Is RGEN the Same as $RGEN?
$RGEN is a common way to refer to the Repligen Corporation ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Repligen Corporation share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
What Is the Repligen Corporation Stock Price Today?
The Repligen Corporation stock price today is 174.86.
What Is the Stock Symbol for Repligen Corporation?
The stock ticker symbol for Repligen Corporation is RGEN.
Is RGEN the Same as $RGEN?
$RGEN is a common way to refer to the Repligen Corporation ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Repligen Corporation share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
174.36
194.36
52 wk Range
100.99
198.87
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
174.36194.36
52 wk Range
100.99198.87
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RGEN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
194.95
Upside
+11.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Freshworks to join S&P SmallCap 600 index- Investing.com
Pro
Form 4 Repligen Corporation For: 6 October- Investing.com
Form 144 REPLIGEN CORP For: 5 October- Investing.com
- Repligen Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 4 Repligen Corporation For: 6 October
- Investing.com
Repligen completes acquisition of BioLife Solutions- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
18 Buy
4 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 194.95
(+11.49% Upside)
Repligen Corporation SWOT Analysis
Analyst Perspectives | Price targets range from $150 to $220, with an average of $172.50, reflecting varied views on Repligen's growth potential and market position |
Market Expansion | Explore Repligen's growth from a $4B addressable market in 2020 to $12B in 2024, driven by new modalities and digitization initiatives |
Financial Resilience | Q1 2025 revenue surpassed expectations at $169.2M, with revised full-year guidance of $695M-$720M, despite earnings per share missing forecasts |
Bioprocessing Pionee | Repligen leads the bioprocessing industry with innovative products and strategic acquisitions, navigating market recovery and industry challenges |
Repligen Corporation Earnings Call Summary for Q2/2026
- Repligen Q2 adjusted EPS of $0.54 beat estimates by 20%; revenue rose 12% YoY to $204M, topping forecasts by $2.53M amid strong demand.
- Company raised FY2026 guidance: revenue $813M-$834M (10.5%-13.5% organic growth), adjusted EPS $2.03-$2.09, operating margin 15.7%-16.0%.
- Proteins segment surged 50%, analytics grew 30%+; filtration remained weak with mid-single-digit growth expected due to Polymem sale and headwinds.
- Shares jumped 6.21% premarket to $139.20; company delivered 12th consecutive quarter meeting or beating expectations, signaling sustained execution.
- BioLife acquisition expected to close Q4, expanding cell therapy strategy; management noted Q3 margins will be lowest of year due to product mix.
Last Updated: 07/28/2026, 09:15 AM
Read Full TranscriptRepligen investor slides for Q2/2026
Last Update: Jul 28, 2026
See full investor slides
Earnings
Latest Release
Jul 28, 2026
EPS / Forecast
0.54 / 0.45
Revenue / Forecast
204M / 201.47M
Compare RGEN to Peers and Sector
Metrics to compare | RGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | 237.6x | −0.5x | −0.3x | |
PEG Ratio | 0.60 | 0.04 | 0.00 | |
Price / Book | 4.7x | 5.0x | 2.6x | |
Price / LTM Sales | 12.6x | 3.6x | 3.0x | |
Upside (Analyst Target) | 11.5% | 8.6% | 58.2% | |
Fair Value Upside | Unlock | 4.7% | 7.5% | Unlock |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Repligen (RGEN) Stock Price Today?
The Repligen stock price today is 174.86 USD.
What Stock Exchange Does Repligen Trade On?
Repligen is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Repligen?
The stock symbol for Repligen is "RGEN."
What Is the Repligen Market Cap?
As of today, Repligen market cap is 9.87B USD.
What Is Repligen's Earnings Per Share (TTM)?
The Repligen EPS (TTM) is 0.73.
When Is the Next Repligen Earnings Date?
Repligen will release its next earnings report on Nov 03, 2026.
From a Technical Analysis Perspective, Is RGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Repligen Stock Split?
Repligen has split 0 times.
How Many Employees Does Repligen Have?
Repligen has 2000 employees.
What is the current trading status of Repligen (RGEN)?
As of Oct 07, 2026, Repligen (RGEN) is trading at a price of 174.86 USD, with a previous close of 174.86 USD. The stock has fluctuated within a day range of 174.36 USD to 194.36 USD, while its 52-week range spans from 100.99 USD to 198.87 USD.
What Is Repligen (RGEN) Price Target According to Analysts?
The average 12-month price target for Repligen is 194.95 USD, with a high estimate of 225 USD and a low estimate of 145 USD. 18 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +11.49% Upside potential.
What Is the RGEN Premarket Price?
RGEN's last pre-market stock price is 176.80 USD. The pre-market share volume is 10.00, and the stock has decreased by 1.94, or 1.11%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.